Time to include buprenorphine-naloxone combination in the WHO model list of essential medicines
DOI:
https://doi.org/10.5055/jom.2013.0164Keywords:
opioid dependence, Buprenorphine, Buprenorphine/naloxoneAbstract
No abstractReferences
WHO: WHO Model List of Essential Medicines—18th List. World Health Organization, 2013.
Systematic review of the safety of buprenorphine, methadone and naltrexone. Department of Therapeutics and Medicines, Center for the AIDS Programme of Research in South Africa, Congella, South Africa, 2007. Available at http://www.who.int/substance_abuse/activities/buprenorphine_methadone_naltrexone.pdf. Accessed July 12, 2013.
Grissinger M: Keeping patients safe from methadone overdoses. P T. 2011; 36: 462-466.
Mattick RP, Kimber J, Breen C, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008: CD002207.
Yokell MA, Zaller ND, Green TC, et al.: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4: 28-41.
Orman JS, Keating GM: Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs. 2009; 69: 577-607.
United States Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol 40 (TIP 40): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction; 2004.
Schackman BR, Leff JA, Polsky D, et al.: Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012; 27: 669-676.
WHO: The Global Burden of Disease: 2004 Update. Switzerland: World Health Organization, 2008.
Downloads
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved